Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2-advanced breast cancer (BC)

被引：60

作者：

Finn, R. S.

Crown, J. P.

Lang, I.

Boer, K.

Bondarenko, I. M.

Kulyk, S. O.

Ettl, J.

Patel, R.

Pinter, T.

Schmidt, M.

Shparyk, Y.

Thummala, A. R.

Voytko, N. L.

Breazna, A.

Kim, S. T.

Randolph, S.

Slamon, D. J.

机构：

[1] Univ Calif Los Angeles, Los Angeles, CA USA

[2] Irish Cooperat Oncol Res Grp, Dublin, Ireland

[3] Orszagos Onkologiai Int, Budapest, Hungary

[4] Szent Margit Korhaz, Budapest, Hungary

[5] Tech Univ Munich, D-80290 Munich, Germany

[6] Comprehens Blood & Canc Ctr, Bakersfield, CA USA

[7] Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary

[8] Univ Hosp Mainz, Mainz, Germany

[9] Lviv State Oncol Reg Treatment & Diagnost Ctr, Lvov, Ukraine

[10] Comprehens Canc Ctr Nevada, Henderson, NV USA

[11] Kyiv City Clin Oncol Ctr, Kiev, Ukraine

[12] Pfizer Oncol, New York, NY USA

[13] Pfizer Oncol, San Diego, CA USA

来源：

关键词：

D O I：

10.1158/0008-5472.SABCS12-S1-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

S1-6

引用

页数：1